The Burrill Report: Genzyme Ready To Spend On Personalized Medicine (.MP3,8.75 Mb)

Recently Genzyme CEO Henri Termeer was quoted as saying he was ready to go on as much as a $600 million shopping spree for new personalized medicine treatments. Big Pharma companies are no different. They’ve embraced personalized medicine as a central part of their future as key patents expire, generic competition grows, and demands to demonstrate the value of their medicines increase.  We spoke to The Burrill Report’s editor Peter Winter about Termeer’s comments and the growing personalized medicine trend within Big Pharma.